alogliptin + glyburide

Alogliptin + glyburide is a fixed-dose combination of two oral antidiabetic agents used to manage type 2 diabetes mellitus. Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin levels (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon release, which helps lower blood glucose[8][4][1]. Glyburide is a sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to sulfonylurea receptors, leading to increased endogenous insulin secretion[3][2]. The combination targets different mechanisms in glucose regulation for improved glycemic control in adults with type 2 diabetes.